Table 4 Associations between CSFP and CSF biomarkers of AD and Qalb values

Aβ1–42 (pg/ml)

1.21

0.99

0.10

1.21

0.23

-0.77-3.17

Aβ1–40 (pg/ml)

10.55

13.77

0.06

0.76

0.44

-16.71-37.81

t-tau (pg/ml)

13.58

9.03

0.13

1.50

0.13

-4.29-31.29

p-tau181 (pg/ml)

-0.11

0.31

0.03

0.33

0.73

-0.51-0.72

Aβ1–42/Aβ1–40

-3.62

8.7 × 10-5

-0.03

-0.41

0.68

-2.1 × 10-4-1.3 × 10-4

p-tau181/Aβ1–42

2.8 × 10-4

0.001

0.02

0.26

0.79

-0.002-0.002

Qalb

-0.03

0.01

-0.21

-2.79

0.006

-0.05-0.01

AD patients

Aβ1–42 (pg/ml)

0.94

1.15

0.07

0.81

0.41

-1.35-3.23

Aβ1–40 (pg/ml)

16.93

16.53

0.10

1.02

0.31

-15.88-49.74

t-tau (pg/ml)

16.08

11.56

0.13

1.39

0.16

-6.87-39.03

p-tau181 (pg/ml)

0.06

0.40

0.01

0.16

0.86

-0.72-0.86

Aβ1–42/Aβ1–40

1.2 × 10-4

1.0 × 10-4

-0.12

-1.26

0.21

-3.2 × 10-4-7.2 × 10-5

p-tau181/Aβ1–42

2.8 × 10-4

0.001

0.02

0.21

0.83

-0.002-0.003

Qalb

-0.04

0.15

-0.24

-2.78

0.006

-0.07-0.01

LBD patients

Aβ1–42 (pg/ml)

4.22

2.01

0.46

2.09

0.04

0.02–8.42

Aβ1–40 (pg/ml)

4.55

23.65

0.04

0.19

0.84

-44.78-53.89

t-tau (pg/ml)

1.69

1.71

0.21

0.99

0.33

-1.87-5.27

p-tau181 (pg/ml)

0.12

0.18

0.15

0.69

0.49

-0.25-0.51

Aβ1–42/Aβ1–40

3.0 × 10-4

1.8 × 10-4

0.36

1.59

0.12

-9.3 × 10-5-0.001

p-tau181/Aβ1–42

2.2 × 10-4

0.001

-0.06

-0.27

0.78

-0.002-0.001

Qalb

-0.01

0.01

-0.17

-0.86

0.39

-0.05-0.02